Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment

Masato Nishimura, Eun Jung Jung, Maitri Y. Shah, Chunhua Lu, Riccardo Spizzo, Masayoshi Shimizu, Hee Dong Han, Cristina Ivan, Simona Rossi, Xinna Zhang, Milena S. Nicoloso, Sherry Y. Wu, Maria Ines Almeida, Justin Bottsford-Miller, Chad V. Pecot, Behrouz Zand, Koji Matsuo, Mian M. Shahzad, Nicholas B. Jennings, Cristian Rodriguez-AguayoGabriel Lopez-Berestein, Anil K. Sood, George A. Calin

Research output: Contribution to journalArticle

Abstract

Development of improved RNA interference-based strategies is of utmost clinical importance. Although siRNA-mediated silencing of EphA2, an ovarian cancer oncogene, results in reduction of tumor growth, we present evidence that additional inhibition of EphA2 by a microRNA (miRNA) further "boosts" its antitumor effects. We identified miR-520d-3p as a tumor suppressor upstream of EphA2, whose expression correlated with favorable outcomes in two independent patient cohorts comprising 647 patients. Restoration of miR-520d-3p prominently decreased EphA2 protein levels, and suppressed tumor growth and migration/invasion both in vitro and in vivo. Dual inhibition of EphA2 in vivo using 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) nanoliposomes loaded with miR-520d-3p and EphA2 siRNA showed synergistic antitumor efficiency and greater therapeutic efficacy than either monotherapy alone. This synergy is at least in part due to miR-520d-3p targeting EphB2, another Eph receptor. Our data emphasize the feasibility of combined miRNA-siRNA therapy, and will have broad implications for innovative gene silencing therapies for cancer and other diseases. SIGNIFICANCE: This study addresses a new concept of RNA inhibition therapy by combining miRNA and siRNA in nanoliposomal particles to target oncogenic pathways altered in ovarian cancer. Combined targeting of the Eph pathway using EphA2 -targeting siRNA and the tumor suppressor miR-520d-3p exhibits remarkable therapeutic synergy and enhanced tumor suppression in vitro and in vivo compared with either monotherapy alone.

Original languageEnglish
Pages (from-to)1302-1315
Number of pages14
JournalCancer Discovery
Volume3
Issue number11
DOIs
Publication statusPublished - Nov 2013

Fingerprint

MicroRNAs
Ovarian Neoplasms
Small Interfering RNA
Neoplasms
EphA2 Receptor
EphA1 Receptor
Therapeutics
Investigational Therapies
Gene Silencing
Growth
RNA Interference
Phosphatidylcholines
Oncogenes
Genetic Therapy
RNA

ASJC Scopus subject areas

  • Oncology

Cite this

Nishimura, M., Jung, E. J., Shah, M. Y., Lu, C., Spizzo, R., Shimizu, M., ... Calin, G. A. (2013). Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discovery, 3(11), 1302-1315. https://doi.org/10.1158/2159-8290.CD-13-0159

Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. / Nishimura, Masato; Jung, Eun Jung; Shah, Maitri Y.; Lu, Chunhua; Spizzo, Riccardo; Shimizu, Masayoshi; Han, Hee Dong; Ivan, Cristina; Rossi, Simona; Zhang, Xinna; Nicoloso, Milena S.; Wu, Sherry Y.; Almeida, Maria Ines; Bottsford-Miller, Justin; Pecot, Chad V.; Zand, Behrouz; Matsuo, Koji; Shahzad, Mian M.; Jennings, Nicholas B.; Rodriguez-Aguayo, Cristian; Lopez-Berestein, Gabriel; Sood, Anil K.; Calin, George A.

In: Cancer Discovery, Vol. 3, No. 11, 11.2013, p. 1302-1315.

Research output: Contribution to journalArticle

Nishimura, M, Jung, EJ, Shah, MY, Lu, C, Spizzo, R, Shimizu, M, Han, HD, Ivan, C, Rossi, S, Zhang, X, Nicoloso, MS, Wu, SY, Almeida, MI, Bottsford-Miller, J, Pecot, CV, Zand, B, Matsuo, K, Shahzad, MM, Jennings, NB, Rodriguez-Aguayo, C, Lopez-Berestein, G, Sood, AK & Calin, GA 2013, 'Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment', Cancer Discovery, vol. 3, no. 11, pp. 1302-1315. https://doi.org/10.1158/2159-8290.CD-13-0159
Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M et al. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discovery. 2013 Nov;3(11):1302-1315. https://doi.org/10.1158/2159-8290.CD-13-0159
Nishimura, Masato ; Jung, Eun Jung ; Shah, Maitri Y. ; Lu, Chunhua ; Spizzo, Riccardo ; Shimizu, Masayoshi ; Han, Hee Dong ; Ivan, Cristina ; Rossi, Simona ; Zhang, Xinna ; Nicoloso, Milena S. ; Wu, Sherry Y. ; Almeida, Maria Ines ; Bottsford-Miller, Justin ; Pecot, Chad V. ; Zand, Behrouz ; Matsuo, Koji ; Shahzad, Mian M. ; Jennings, Nicholas B. ; Rodriguez-Aguayo, Cristian ; Lopez-Berestein, Gabriel ; Sood, Anil K. ; Calin, George A. / Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. In: Cancer Discovery. 2013 ; Vol. 3, No. 11. pp. 1302-1315.
@article{4e1f8ddcb94f4e75ba8951692761038b,
title = "Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment",
abstract = "Development of improved RNA interference-based strategies is of utmost clinical importance. Although siRNA-mediated silencing of EphA2, an ovarian cancer oncogene, results in reduction of tumor growth, we present evidence that additional inhibition of EphA2 by a microRNA (miRNA) further {"}boosts{"} its antitumor effects. We identified miR-520d-3p as a tumor suppressor upstream of EphA2, whose expression correlated with favorable outcomes in two independent patient cohorts comprising 647 patients. Restoration of miR-520d-3p prominently decreased EphA2 protein levels, and suppressed tumor growth and migration/invasion both in vitro and in vivo. Dual inhibition of EphA2 in vivo using 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) nanoliposomes loaded with miR-520d-3p and EphA2 siRNA showed synergistic antitumor efficiency and greater therapeutic efficacy than either monotherapy alone. This synergy is at least in part due to miR-520d-3p targeting EphB2, another Eph receptor. Our data emphasize the feasibility of combined miRNA-siRNA therapy, and will have broad implications for innovative gene silencing therapies for cancer and other diseases. SIGNIFICANCE: This study addresses a new concept of RNA inhibition therapy by combining miRNA and siRNA in nanoliposomal particles to target oncogenic pathways altered in ovarian cancer. Combined targeting of the Eph pathway using EphA2 -targeting siRNA and the tumor suppressor miR-520d-3p exhibits remarkable therapeutic synergy and enhanced tumor suppression in vitro and in vivo compared with either monotherapy alone.",
author = "Masato Nishimura and Jung, {Eun Jung} and Shah, {Maitri Y.} and Chunhua Lu and Riccardo Spizzo and Masayoshi Shimizu and Han, {Hee Dong} and Cristina Ivan and Simona Rossi and Xinna Zhang and Nicoloso, {Milena S.} and Wu, {Sherry Y.} and Almeida, {Maria Ines} and Justin Bottsford-Miller and Pecot, {Chad V.} and Behrouz Zand and Koji Matsuo and Shahzad, {Mian M.} and Jennings, {Nicholas B.} and Cristian Rodriguez-Aguayo and Gabriel Lopez-Berestein and Sood, {Anil K.} and Calin, {George A.}",
year = "2013",
month = "11",
doi = "10.1158/2159-8290.CD-13-0159",
language = "English",
volume = "3",
pages = "1302--1315",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment

AU - Nishimura, Masato

AU - Jung, Eun Jung

AU - Shah, Maitri Y.

AU - Lu, Chunhua

AU - Spizzo, Riccardo

AU - Shimizu, Masayoshi

AU - Han, Hee Dong

AU - Ivan, Cristina

AU - Rossi, Simona

AU - Zhang, Xinna

AU - Nicoloso, Milena S.

AU - Wu, Sherry Y.

AU - Almeida, Maria Ines

AU - Bottsford-Miller, Justin

AU - Pecot, Chad V.

AU - Zand, Behrouz

AU - Matsuo, Koji

AU - Shahzad, Mian M.

AU - Jennings, Nicholas B.

AU - Rodriguez-Aguayo, Cristian

AU - Lopez-Berestein, Gabriel

AU - Sood, Anil K.

AU - Calin, George A.

PY - 2013/11

Y1 - 2013/11

N2 - Development of improved RNA interference-based strategies is of utmost clinical importance. Although siRNA-mediated silencing of EphA2, an ovarian cancer oncogene, results in reduction of tumor growth, we present evidence that additional inhibition of EphA2 by a microRNA (miRNA) further "boosts" its antitumor effects. We identified miR-520d-3p as a tumor suppressor upstream of EphA2, whose expression correlated with favorable outcomes in two independent patient cohorts comprising 647 patients. Restoration of miR-520d-3p prominently decreased EphA2 protein levels, and suppressed tumor growth and migration/invasion both in vitro and in vivo. Dual inhibition of EphA2 in vivo using 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) nanoliposomes loaded with miR-520d-3p and EphA2 siRNA showed synergistic antitumor efficiency and greater therapeutic efficacy than either monotherapy alone. This synergy is at least in part due to miR-520d-3p targeting EphB2, another Eph receptor. Our data emphasize the feasibility of combined miRNA-siRNA therapy, and will have broad implications for innovative gene silencing therapies for cancer and other diseases. SIGNIFICANCE: This study addresses a new concept of RNA inhibition therapy by combining miRNA and siRNA in nanoliposomal particles to target oncogenic pathways altered in ovarian cancer. Combined targeting of the Eph pathway using EphA2 -targeting siRNA and the tumor suppressor miR-520d-3p exhibits remarkable therapeutic synergy and enhanced tumor suppression in vitro and in vivo compared with either monotherapy alone.

AB - Development of improved RNA interference-based strategies is of utmost clinical importance. Although siRNA-mediated silencing of EphA2, an ovarian cancer oncogene, results in reduction of tumor growth, we present evidence that additional inhibition of EphA2 by a microRNA (miRNA) further "boosts" its antitumor effects. We identified miR-520d-3p as a tumor suppressor upstream of EphA2, whose expression correlated with favorable outcomes in two independent patient cohorts comprising 647 patients. Restoration of miR-520d-3p prominently decreased EphA2 protein levels, and suppressed tumor growth and migration/invasion both in vitro and in vivo. Dual inhibition of EphA2 in vivo using 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) nanoliposomes loaded with miR-520d-3p and EphA2 siRNA showed synergistic antitumor efficiency and greater therapeutic efficacy than either monotherapy alone. This synergy is at least in part due to miR-520d-3p targeting EphB2, another Eph receptor. Our data emphasize the feasibility of combined miRNA-siRNA therapy, and will have broad implications for innovative gene silencing therapies for cancer and other diseases. SIGNIFICANCE: This study addresses a new concept of RNA inhibition therapy by combining miRNA and siRNA in nanoliposomal particles to target oncogenic pathways altered in ovarian cancer. Combined targeting of the Eph pathway using EphA2 -targeting siRNA and the tumor suppressor miR-520d-3p exhibits remarkable therapeutic synergy and enhanced tumor suppression in vitro and in vivo compared with either monotherapy alone.

UR - http://www.scopus.com/inward/record.url?scp=84887467125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887467125&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-13-0159

DO - 10.1158/2159-8290.CD-13-0159

M3 - Article

C2 - 24002999

AN - SCOPUS:84887467125

VL - 3

SP - 1302

EP - 1315

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 11

ER -